


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. **(Currently Amended)** A compound of formula (I)



wherein ring A represents a benzene ring which may have a substituent(s), wherein the substituent(s) is 1 to 5 optional substituent(s) selected from the group of methyl, ethyl, a fluorine atom, a chlorine atom, methoxy, ethoxy, ~~difluoromethoxy, hydroxyl, and acetyl,~~
~~trifluoromethoxy, methylsulfonyl, acetyl amino, methylsulfonylamino, 1-hydroxy-1-methylethyl,~~
~~1-propenyl and cyano;~~

ring B represents a benzene ring which may have a substituent(s), a thiophene ring which may have a substituent(s), an indan ring which may have a substituent(s), or a 1,3-benzodioxole ring which may have a substituent(s), ~~or a cyclopentane ring which may have a substituent(s),~~ wherein the substituent(s) is 1 to 5 optional substituent(s) selected from the group consisting of methyl, ethyl, propyl, a fluorine atom, and a chlorine atom, ~~methoxy and ethoxy;~~

K represents C1-4 alkylene ~~which may be substituted with 1 to 5 optional substituent(s)~~
~~selected from the group consisting of methyl, a fluorine atom, hydroxy, and oxo;~~

Q represents methylene, or ethylene, ~~—O—, or —CH₂—O—~~;

M represents a bond, C1-4 alkenylene which may have a substituent(s), or C2-4 alkenylene which may have a substituent(s), wherein the substituent(s) is 1 to 5 optional substituent(s) ~~selected from the group consisting of methyl and hydroxyl;~~

ring D represents a benzene ring which may have a substituent(s), a pyrrole ring which may have a substituent(s), an imidazole ring ~~which may have a substituent(s);~~ a pyrazole ring which may have a substituent(s), ~~an oxazole ring which may have a substituent(s);~~ or a thiazole ring which may have a substituent(s), ~~or a thiophene ring which may have a substituent(s);~~ wherein the substituent(s) is 1 to 5 optional substituent(s) selected from the group consisting of ~~earboxy,~~ methyl, ~~a fluorine atom, a chlorine atom,~~ and methoxycarbonyl, ~~ethoxycarbonyl,~~ aminocarbonyl, N-methylaminocarbonyl, N,N-dimethylaminocarbonyl, and acetyl;

ring E represents a benzene ring ~~which may have a substituent(s);~~ wherein the substituent(s) is 1 to 5 optional substituent(s) ~~selected from the group consisting of methyl, a chlorine atom, a fluorine atom, methoxy, and ethoxy;~~

L represents a bond, or —CH₂—, —O—, —S—, —SO—, —SO₂— ~~or —NH—~~;


Z represents COOH, CONHSO₂R¹, in which R¹ represents methyl, or C1-8 alkyl ~~which may be substituted,~~ a benzene ring which may have a substituent(s), a pyridine ring which may have a substituent(s) ~~a thiophene ring which may have a substituent(s), a furan ring which may have a substituent(s), a imidazole ring which may have a substituent(s), a thiazole ring which may have a substituent(s), an isoxazole ring which may have a substituent(s), a morpholine ring which may have a substituent(s);~~ wherein the substituent(s) is 1 to 5 optional substituent(s)


selected from the group consisting of methyl, ~~tert-butyl~~, ~~a chlorine atom~~, ~~a fluorine atom~~,
~~trifluoromethyl~~, ~~methoxy~~, ~~trifluoromethoxy~~, and ~~acetyl~~; and

t represents 0 or 1, or

a salt thereof, ~~or a solvate thereof~~.

2. **(Original)** The compound according to claim 1, wherein the compound of formula (I) is an optically active compound of formula (I-A):



wherein  represents β -configuration; and other symbols have the same meanings as described in claim 1.

3.-4. **(Canceled)**


5. **(Previously presented)** The compound according to claim 1, wherein ring B is an indan ring which may have a substituent(s).

6. **(Canceled)**

7. **(Original)** The compound according to claim 1, wherein ring D is a benzene ring which may have a substituent(s), a pyrazole ring which may have a substituent(s) or a pyrrole ring which may have a substituent(s).


8. **(Canceled)**

9. **(Original)** The compound according to claim 1, wherein



is methylene which may be substituted, ethylene which may be substituted, propylene which may be substituted, or ethenylene which may be substituted.

10. **(Currently Amended)** The compound according to claim 1, wherein ring A is a benzene ring which may have a substituent(s);
ring B is an indan ring which may have a substituent(s);
ring D is a benzene ring which may have a substituent(s), a pyrazole ring which may have a substituent(s) or a pyrrole ring which may have a substituent(s);



is methylene which may be substituted, ethylene which may be substituted, propylene which may be substituted, or ethenylene which may be substituted; and

Z is -COOH; -CONHSO₂R¹, in which R¹ is ~~methyl-C1-8 alkyl which may be substituted~~, a benzene ring which may have a substituent(s).

11. **(Original)** The compound according to claim 1, which is selected from the group consisting of:

- (1) {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}acetic acid,
- (2) {1-[(2S)-2-[(S)-(3,5-dimethoxy-4-methylphenyl)(hydroxy)methyl]-5-thien-3-ylpentyl]-1H-pyrrol-3-yl}acetic acid,
- (3) {1-[(2S,3S)-2-(1,3-benzodioxol-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}acetic acid,
- (4) {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxy-3-(3,4,5-trimethoxyphenyl)propyl]-1H-pyrrol-3-yl}acetic acid,
- (5) {1-[(2S,3S)-3-(4-acetyl-3,5-dimethoxyphenyl)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}acetic acid,
- (6) {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(4-ethyl-3,5-dimethoxyphenyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}acetic acid,
- (7) 3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}propanoic acid,

- (8) 3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxy-3-(3,4,5-trimethoxyphenyl)propyl]-1H-pyrrol-3-yl}propanoic acid,
- (9) 3-{1-[(2S,3S)-3-(4-acetyl-3,5-dimethoxyphenyl)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}propanoic acid,
- (10) 3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(4-ethyl-3,5-dimethoxyphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}propanoic acid,
- (11) 2-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}-N-(methylsulfonyl)acetamide,
- (12) [1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-4-(methoxycarbonyl)-1H-pyrrol-3-yl]acetic acid,
- (13) N-{3-[1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl]propanoyl}-2-methylbenzenesulfonamide,
- (14) (2E)-3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acrylic acid,
- (15) 2-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}-2-methylpropanoic acid, and
- (16) (2E)-3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}-2-methylacrylic acid.

12. **(Previously presented)** A pharmaceutical composition comprising the compound of formula (I) according to claim 1, or a salt thereof, ~~or a solvate thereof~~.

13. **(Original)** The pharmaceutical composition according to claim 12, which is an LPA receptor antagonist, wherein the LPA receptor is EDG-2.

14. **(Canceled)**

15. **(Original)** The pharmaceutical composition according to claim 12, which is an agent for prevention and/or treatment for urinary system disease.

16. **(Currently Amended)** A method for treatment of urinary system disease selected from the group of prostatic hypertrophy, neurogenic bladder dysfunction disease, dysuria, pollakiuria, night urination and urodynia, which comprises administering to a mammal an effective amount of the compound of formula (I) according to claim 1, or a salt thereof, ~~or a solvate thereof~~.

17. **(Canceled)**

18. **(Currently Amended)** A pharmaceutical composition comprising a combination of the compound of formula (I) according to claim 1, or a salt thereof, ~~a solvate thereof~~ with at least one agent selected from an LPA receptor antagonist, an $\alpha 1$ blocking agent, an anticholinergic agent, a 5α -reductase inhibitor and an anti-androgenic agent.